vs
RH（RH）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
RH的季度营收约是Revvity的1.1倍（$883.8M vs $772.1M），Revvity净利率更高（12.7% vs 4.1%，领先8.6%），RH同比增速更快（8.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $83.0M），过去两年RH的营收复合增速更高（9.4% vs 9.0%）
RH是美国高端家居品牌，总部位于加利福尼亚州科尔特马德拉。品牌通过线下零售门店、产品目录和线上渠道发售家居商品，截至2018年8月，在美国和加拿大共运营70家展示馆、18家全系列设计展示馆、3家婴童家居展示馆，另有36家奥莱门店。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RH vs RVTY — 直观对比
营收规模更大
RH
是对方的1.1倍
$772.1M
营收增速更快
RH
高出3.0%
5.9%
净利率更高
RVTY
高出8.6%
4.1%
自由现金流更多
RVTY
多$78.8M
$83.0M
两年增速更快
RH
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $883.8M | $772.1M |
| 净利润 | $36.3M | $98.4M |
| 毛利率 | 44.1% | — |
| 营业利润率 | 12.0% | 14.5% |
| 净利率 | 4.1% | 12.7% |
| 营收同比 | 8.9% | 5.9% |
| 净利润同比 | 9.3% | 3.9% |
| 每股收益（稀释后） | $1.83 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RHRVTY
| Q4 25 | $883.8M | $772.1M | ||
| Q3 25 | $899.2M | $698.9M | ||
| Q2 25 | $814.0M | $720.3M | ||
| Q1 25 | $812.4M | $664.8M | ||
| Q4 24 | $811.7M | $729.4M | ||
| Q3 24 | $829.7M | $684.0M | ||
| Q2 24 | $727.0M | $691.7M | ||
| Q1 24 | $738.3M | $649.9M |
净利润RHRVTY
| Q4 25 | $36.3M | $98.4M | ||
| Q3 25 | $51.7M | $46.7M | ||
| Q2 25 | $8.0M | $53.9M | ||
| Q1 25 | $13.9M | $42.2M | ||
| Q4 24 | $33.2M | $94.6M | ||
| Q3 24 | $29.0M | $94.4M | ||
| Q2 24 | $-3.6M | $55.4M | ||
| Q1 24 | $11.4M | $26.0M |
毛利率RHRVTY
| Q4 25 | 44.1% | — | ||
| Q3 25 | 45.5% | 53.6% | ||
| Q2 25 | 43.7% | 54.5% | ||
| Q1 25 | 44.7% | 56.5% | ||
| Q4 24 | 44.5% | — | ||
| Q3 24 | 45.2% | 56.3% | ||
| Q2 24 | 43.5% | 55.7% | ||
| Q1 24 | 43.5% | 54.6% |
营业利润率RHRVTY
| Q4 25 | 12.0% | 14.5% | ||
| Q3 25 | 14.3% | 11.7% | ||
| Q2 25 | 6.9% | 12.6% | ||
| Q1 25 | 8.7% | 10.9% | ||
| Q4 24 | 12.5% | 16.3% | ||
| Q3 24 | 11.6% | 14.3% | ||
| Q2 24 | 7.5% | 12.4% | ||
| Q1 24 | 8.7% | 6.8% |
净利率RHRVTY
| Q4 25 | 4.1% | 12.7% | ||
| Q3 25 | 5.8% | 6.7% | ||
| Q2 25 | 1.0% | 7.5% | ||
| Q1 25 | 1.7% | 6.4% | ||
| Q4 24 | 4.1% | 13.0% | ||
| Q3 24 | 3.5% | 13.8% | ||
| Q2 24 | -0.5% | 8.0% | ||
| Q1 24 | 1.5% | 4.0% |
每股收益（稀释后）RHRVTY
| Q4 25 | $1.83 | $0.86 | ||
| Q3 25 | $2.62 | $0.40 | ||
| Q2 25 | $0.40 | $0.46 | ||
| Q1 25 | $0.71 | $0.35 | ||
| Q4 24 | $1.66 | $0.77 | ||
| Q3 24 | $1.45 | $0.77 | ||
| Q2 24 | $-0.20 | $0.45 | ||
| Q1 24 | $0.91 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $43.1M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.3M | $7.3B |
| 总资产 | $4.8B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RHRVTY
| Q4 25 | $43.1M | $919.9M | ||
| Q3 25 | $34.6M | $931.4M | ||
| Q2 25 | $46.1M | $991.8M | ||
| Q1 25 | $30.4M | $1.1B | ||
| Q4 24 | $87.0M | $1.2B | ||
| Q3 24 | $78.3M | $1.2B | ||
| Q2 24 | $101.8M | $2.0B | ||
| Q1 24 | $123.7M | $1.7B |
股东权益RHRVTY
| Q4 25 | $3.3M | $7.3B | ||
| Q3 25 | $-40.9M | $7.4B | ||
| Q2 25 | $-110.8M | $7.6B | ||
| Q1 25 | $-163.6M | $7.6B | ||
| Q4 24 | $-183.0M | $7.7B | ||
| Q3 24 | $-234.7M | $7.9B | ||
| Q2 24 | $-289.9M | $7.9B | ||
| Q1 24 | $-297.4M | $7.8B |
总资产RHRVTY
| Q4 25 | $4.8B | $12.2B | ||
| Q3 25 | $4.7B | $12.1B | ||
| Q2 25 | $4.7B | $12.4B | ||
| Q1 25 | $4.6B | $12.4B | ||
| Q4 24 | $4.5B | $12.4B | ||
| Q3 24 | $4.4B | $12.8B | ||
| Q2 24 | $4.2B | $13.4B | ||
| Q1 24 | $4.1B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $131.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $83.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 9.4% | 21.0% |
| 资本支出强度资本支出/营收 | 5.5% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.64× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $128.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流RHRVTY
| Q4 25 | $131.9M | $182.0M | ||
| Q3 25 | $137.7M | $138.5M | ||
| Q2 25 | $86.6M | $134.3M | ||
| Q1 25 | $-18.8M | $128.2M | ||
| Q4 24 | $-31.4M | $174.2M | ||
| Q3 24 | $11.2M | $147.9M | ||
| Q2 24 | $56.1M | $158.6M | ||
| Q1 24 | $-114.0M | $147.6M |
自由现金流RHRVTY
| Q4 25 | $83.0M | $161.8M | ||
| Q3 25 | $80.7M | $120.0M | ||
| Q2 25 | $34.1M | $115.5M | ||
| Q1 25 | $-69.7M | $112.2M | ||
| Q4 24 | $-96.0M | $149.8M | ||
| Q3 24 | $-37.9M | $125.6M | ||
| Q2 24 | $-10.1M | $136.6M | ||
| Q1 24 | $-251.5M | $129.7M |
自由现金流率RHRVTY
| Q4 25 | 9.4% | 21.0% | ||
| Q3 25 | 9.0% | 17.2% | ||
| Q2 25 | 4.2% | 16.0% | ||
| Q1 25 | -8.6% | 16.9% | ||
| Q4 24 | -11.8% | 20.5% | ||
| Q3 24 | -4.6% | 18.4% | ||
| Q2 24 | -1.4% | 19.7% | ||
| Q1 24 | -34.1% | 20.0% |
资本支出强度RHRVTY
| Q4 25 | 5.5% | 2.6% | ||
| Q3 25 | 6.3% | 2.6% | ||
| Q2 25 | 6.5% | 2.6% | ||
| Q1 25 | 6.3% | 2.4% | ||
| Q4 24 | 8.0% | 3.4% | ||
| Q3 24 | 5.9% | 3.3% | ||
| Q2 24 | 9.1% | 3.2% | ||
| Q1 24 | 18.6% | 2.7% |
现金转化率RHRVTY
| Q4 25 | 3.64× | 1.85× | ||
| Q3 25 | 2.66× | 2.97× | ||
| Q2 25 | 10.78× | 2.49× | ||
| Q1 25 | -1.35× | 3.03× | ||
| Q4 24 | -0.95× | 1.84× | ||
| Q3 24 | 0.39× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | -10.01× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RH
| RH Segment | $835.8M | 95% |
| Waterworks Segment | $48.0M | 5% |
| Gift Card And Merchandise Credit | $4.5M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
